Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OWL-1410-AI
- Development stage
- Preclinical
- Lead developer
- Owl Therapeutics
- Modality
- Small Molecules
01
Overview
OWL-1410-AI is a discovery-stage, generative AI-engineered small molecule variant being developed by Owl Therapeutics for the treatment of traumatic brain injury (TBI). Part of a platform focused on 'supercharged microglial' therapeutics, the compound is designed to enhance and protect microglia—the brain's resident immune cells—to address the neuroinflammatory response associated with TBI. It is a variant of the company's lead clinical asset, OWL-1410 (NeuroSTAT®), which was licensed from Abliva AB. OWL-1410-AI is currently in the discovery phase of development and utilizes generative AI and machine learning technologies to optimize its neurotherapeutic properties.
Beyond the preview
Go deeper on OWL-1410-AI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OWL-1410-AI.